Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Eribulin Mesylate

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   30529   clinical trials with a EudraCT protocol, of which   4716   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    Select Age Range:
    Select Trial Status:
    Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    11 result(s) found for: Eribulin Mesylate . Displaying page 1 of 1.
    EudraCT Number: 2013-004600-19 Sponsor Protocol Number: PAINTER01 Start Date*: 2014-01-21
    Sponsor Name:Azienda Ospedaliera Fatebenefratelli e Oftalmico - Milano, Italy
    Full Title: Multicenter, interventional, single-arm, phase IV study evaluating tolerability of Eribulin and its relationship with a set of polymorphisms in an unselected population of female patients with meta...
    Medical condition: Patients with metastatic breast cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004225-14 Sponsor Protocol Number: PQR309-007 Start Date*: 2016-01-19
    Sponsor Name:PIQUR Therapeutics AG
    Full Title: An open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients with locally advanced or metastatic HER2 negative and tr...
    Medical condition: Locally advanced or metastatic HER2 negative and triple-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    18.1 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003505-10 Sponsor Protocol Number: ERIGE Start Date*: 2013-04-24
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA
    Full Title: Phase II study of Eribulin in combination with Gemcitabine for the First-line Treatment of Patients with Locally Recurrent or Metastatic Triple Negative Breast Cancer. Protocol ERIGE.
    Medical condition: Locally recurrent or metastatic triple negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10006197 Breast cancer NOS stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011217-24 Sponsor Protocol Number: E7389-E044-203 Start Date*: 2009-12-03
    Sponsor Name:Eisai Ltd
    Full Title: A Phase 1b/2, Multicenter, Open-label, Dose-escalation and Confirmation Study of Eribulin in Combination with Capecitabine
    Medical condition: Phase 1 - Advanced and/or metastatic cancer Phase 2 - Advanced and/or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10027477 Metastatic carcinoma LLT
    17.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Ongoing) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002395-24 Sponsor Protocol Number: PM60184-B-001-15 Start Date*: 2015-12-09
    Sponsor Name:Pharma Mar, S.A. , Sociedad Unipersonal
    Full Title: Phase II, Open-Label, Randomized, Controlled Study of PM060184 in Advanced, Hormone Receptor Positive, HER2 negative Breast Cancer Patients in Third or Fourth Line Setting.
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002453-38 Sponsor Protocol Number: 15-102-14 Start Date*: 2017-01-17
    Sponsor Name:Nektar Therapeutics
    Full Title: A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been...
    Medical condition: Metastatic breast cancer with stable brain metastases
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002716-28 Sponsor Protocol Number: 673-301 Start Date*: 2014-05-03
    Sponsor Name:Medivation, Inc.
    Full Title: A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic ...
    Medical condition: Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Ongoing) BE (Ongoing) IT (Ongoing) IE (Ongoing) FR (Ongoing) ES (Ongoing) DE (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003400-24 Sponsor Protocol Number: I3Y-MC-JPBZ Start Date*: 2016-01-29
    Sponsor Name:Lilly S.A.
    Full Title: monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physic...
    Medical condition: Hormone receptor positive, HER2-positive advanced breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) GR (Ongoing) BE (Ongoing) GB (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001949-34 Sponsor Protocol Number: E7389-G000-305 Start Date*: 2006-10-02
    Sponsor Name:Eisai Limited
    Full Title: A Phase III Open Label, Randomized Parallel Two-Arm Multi Center Study of E7389 versus ‘Treatment of Physician’s Choice’ in Patients with Locally Recurrent or Metastatic Breast Cancer, Previously T...
    Medical condition: Locally recurrent or metastatic breast cancer after failure of multiple prior chemotherapy regimens
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) HU (Completed) DE (Completed) GB (Ongoing) CZ (Ongoing) FR (Ongoing) IT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-024483-17 Sponsor Protocol Number: E7389-G000-309 Start Date*: 2011-06-30
    Sponsor Name:Eisai Ltd
    Full Title: A Randomised, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.
    Medical condition: Soft tissue sarcoma (STS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) GB (Ongoing) AT (Completed) DK (Completed) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003832-30 Sponsor Protocol Number: 11-PIR-11 Start Date*: 2012-06-21
    Sponsor Name:Nektar Therapeutics
    Full Title: The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Locally Recurr...
    Medical condition: Locally Recurrent Breast Cancer, Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (Ongoing) DE (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-Sat Jun 24 18:21:40 BST 2017 | 30 Churchill Place, Canary Wharf, London E14 5EU
    Legal notice
    EMA HMA